Christopher Kenney
Chief Tech/Sci/R&D Officer bij XENON PHARMACEUTICALS INC.
Vermogen: - $ op 31-03-2024
Profiel
Christopher Kenney is currently the Chief Medical Officer at Xenon Pharmaceuticals, Inc. He previously worked as the Senior Vice President-Medical Affairs at Acorda Therapeutics, Inc. from 2016 to 2019, as the Chief Medical Officer at Cadent Therapeutics, Inc. from 2019 to 2020, and as the Senior Vice President-Clinical Development at Biotie Therapies, Inc. from 2013 to 2016.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 11-03-2024 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Christopher Kenney
| Bedrijven | Functie | Begin |
|---|---|---|
| XENON PHARMACEUTICALS INC. | Chief Tech/Sci/R&D Officer | 23-08-2021 |
Eerdere bekende functies van Christopher Kenney
| Bedrijven | Functie | Einde |
|---|---|---|
Cadent Therapeutics, Inc.
 Cadent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cadent Therapeutics, Inc. develops novel small molecule therapeutics to treat schizophrenia and other cognitive disorders. It focuses on modulating synaptic plasticity, the mechanism through which the brain builds and evolves the synaptic networks that carry out cognitive functions such as learning and memory. The company was founded by Kollol Pal, Frank S. Menniti, and Bertrand Leo Chenard in 2010 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | 01-12-2020 |
| ACORDA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01-01-2019 |
| Biotie Therapies, Inc. | Chief Tech/Sci/R&D Officer | 01-01-2016 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| ACORDA THERAPEUTICS, INC. | Health Technology |
| XENON PHARMACEUTICALS INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Cadent Therapeutics, Inc.
Cadent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cadent Therapeutics, Inc. develops novel small molecule therapeutics to treat schizophrenia and other cognitive disorders. It focuses on modulating synaptic plasticity, the mechanism through which the brain builds and evolves the synaptic networks that carry out cognitive functions such as learning and memory. The company was founded by Kollol Pal, Frank S. Menniti, and Bertrand Leo Chenard in 2010 and is headquartered in Cambridge, MA. | Health Technology |
| Biotie Therapies, Inc. |
